{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:02:28Z","timestamp":1782316948857,"version":"3.54.5"},"reference-count":120,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.08.032","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T10:46:16Z","timestamp":1597833976000},"page":"6487-6499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present \u03b1-gal epitopes"],"prefix":"10.1016","volume":"38","author":[{"given":"Uri","family":"Galili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.08.032_b0005","article-title":"Vaccines for COVID-19: The current state of play [published online ahead of print, 2020 Jun 18]","author":"Koirala","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.vaccine.2020.08.032_b0010","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 Vaccines: Status Report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2020.08.032_b0015","first-page":"1","article-title":"The SARS-CoV-2 Vaccine Pipeline: an Overview [published online ahead of print, 2020 Mar 3]","author":"Chen","year":"2020","journal-title":"Curr Trop Med Rep"},{"key":"10.1016\/j.vaccine.2020.08.032_b0020","doi-asserted-by":"crossref","unstructured":"Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Coronavirus membrane fusion mechanism offers as a potential target for antiviral development [published online ahead of print, 2020 Apr 6]. Antiviral Res 2020;104792.","DOI":"10.1016\/j.antiviral.2020.104792"},{"key":"10.1016\/j.vaccine.2020.08.032_b0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.08.032_b0030","doi-asserted-by":"crossref","unstructured":"Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020;94: e00127\u201320.","DOI":"10.1128\/JVI.00127-20"},{"key":"10.1016\/j.vaccine.2020.08.032_b0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0040","doi-asserted-by":"crossref","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. The Lancet, Published online July 20, 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)31604-4.","DOI":"10.1016\/S0140-6736(20)31604-4"},{"key":"10.1016\/j.vaccine.2020.08.032_b0045","doi-asserted-by":"crossref","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report. N Engl J Med July 14, 2020. https:\/\/doi.org\/10.1056\/NEJMoa2022483.","DOI":"10.1056\/NEJMoa2022483"},{"key":"10.1016\/j.vaccine.2020.08.032_b0050","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0264-410X(99)00507-1","article-title":"Immunity to influenza in the elderly","volume":"18","author":"Webster","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0055","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1385\/IR:29:1-3:113","article-title":"Immunity to influenza: the challenges of protecting an aging population","volume":"29","author":"Katz","year":"2004","journal-title":"Immunol Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0060","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1016\/j.vaccine.2012.05.016","article-title":"Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients","volume":"30","author":"Chang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0065","doi-asserted-by":"crossref","unstructured":"Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020 [published online ahead of print, 2020 Mar 27].","DOI":"10.1016\/j.jinf.2020.03.005"},{"key":"10.1016\/j.vaccine.2020.08.032_b0070","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343\u20136.","DOI":"10.15585\/mmwr.mm6912e2"},{"key":"10.1016\/j.vaccine.2020.08.032_b0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.virol.2004.05.017","article-title":"Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein","volume":"326","author":"Han","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2020.08.032_b0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nsmb.3293","article-title":"Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy","volume":"23","author":"Walls","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0085","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1073\/pnas.1908898117","article-title":"Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans","volume":"117","author":"Yang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0090","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science [published online ahead of print, 2020 May 4] 2020.","DOI":"10.1101\/2020.03.26.010322"},{"key":"10.1016\/j.vaccine.2020.08.032_b0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.032_b0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.08.032_b0105","doi-asserted-by":"crossref","first-page":"24ra21","DOI":"10.1126\/scitranslmed.3000799","article-title":"Cross-neutralization of 1918 and 2009 influenza viruses: Role of glycans in viral evolution and vaccine design","volume":"2","author":"Wei","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1126\/science.1186430","article-title":"Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus","volume":"328","author":"Xu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.032_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004932","article-title":"Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site","volume":"11","author":"Crooks","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.08.032_b0120","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/S0021-9258(18)86956-3","article-title":"Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells","volume":"265","author":"Leonard","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0125","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1016\/S0021-9258(19)38919-7","article-title":"Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues","volume":"265","author":"Mizuochi","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0130","series-title":"The natural anti-Gal antibody as foe turned friend in medicine","author":"Book","year":"2018"},{"key":"10.1016\/j.vaccine.2020.08.032_b0135","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1128\/JVI.00310-06","article-title":"Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Gal\u03b11-3Gal\u03b21-4GlcNAc-R epitopes","volume":"80","author":"Abdel-Motal","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0140","doi-asserted-by":"crossref","first-page":"9131","DOI":"10.1128\/JVI.00647-07","article-title":"Immunogenicity of influenza virus vaccine is increased by anti-Gal-mediated targeting to antigen-presenting cells","volume":"81","author":"Abdel-Motal","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0145","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.vaccine.2009.12.015","article-title":"Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120\/p24 fusion protein vaccine expressing \u03b1-gal epitopes","volume":"28","author":"Abdel-Motal","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0150","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/j.vaccine.2009.03.019","article-title":"Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody","volume":"27","author":"Abdel-Motal","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0155","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4049\/jimmunol.91.6.761","article-title":"Enhanced antitoxin responses in irradiated mice elicited by complexes of tetanus toxoid and specific antibody","volume":"91","author":"Stoner","year":"1963","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1084\/jem.173.1.37","article-title":"Effect of antigen\/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies","volume":"173","author":"Manca","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0165","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1126\/science.6231724","article-title":"Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen","volume":"224","author":"Celis","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.032_b0170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/infdis\/135.4.600","article-title":"Inactivated Venezuelan equine encephalomyelitis virus vaccine complexed with specific antibody: enhanced primary immune response and altered pattern of antibody class elicited","volume":"135","author":"Houston","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.032_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.77.1.10-24.2003","article-title":"Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques","volume":"77","author":"Villinger","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0180","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1073\/pnas.95.2.652","article-title":"Fc receptors are required in passive and active immunity to melanoma","volume":"95","author":"Clynes","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1172\/JCI0215640","article-title":"Immune complex-mediated antigen presentation induces tumor immunity","volume":"110","author":"Rafiq","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.08.032_b0190","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1084\/jem.189.2.371","article-title":"Fc\u03b3 receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization","volume":"189","author":"Regnault","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0195","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.4049\/jimmunol.168.5.2240","article-title":"Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo","volume":"168","author":"Schuurhuis","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1084\/jem.160.5.1519","article-title":"A unique natural human IgG antibody with anti-\u03b1-galactosyl specificity","volume":"160","author":"Galili","year":"1984","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12110","article-title":"Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits","volume":"140","author":"Galili","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2020.08.032_b0210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/cdli.2.2.125-131.1995","article-title":"Anti-\u03b1-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions","volume":"2","author":"Hamadeh","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0215","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/iai.56.7.1730-1737.1988","article-title":"Interaction between human natural anti-\u03b1-galactosyl immunoglobulin G and bacteria of the human flora","volume":"56","author":"Galili","year":"1988","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.032_b0220","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1128\/IAI.70.11.6215-6222.2002","article-title":"Induction of cytolytic anti-Gal antibodies in \u03b1-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria","volume":"70","author":"Posekany","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.08.032_b0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1034\/j.1399-3089.2001.00082.x","article-title":"Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural \u03b1-galactosyl IgG antibodies","volume":"8","author":"Ma\u00f1ez","year":"2001","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0230","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1084\/jem.162.2.573","article-title":"Human natural anti-\u03b1-galactosyl IgG. II. The specific recognition of \u03b1(1\u20133)-linked galactose residues","volume":"162","author":"Galili","year":"1985","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1084\/jem.166.2.419","article-title":"Circulating antibodies to mouse laminin in Chagas disease, American cutaneous leishmaniasis, and normal individuals recognize terminal galactosyl(\u03b11-3)-galactose epitopes","volume":"166","author":"Towbin","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0240","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1073\/pnas.84.5.1369","article-title":"Evolutionary relationship between the anti-Gal antibody and the Gal\u03b11-3Gal epitope in primates","volume":"84","author":"Galili","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0245","doi-asserted-by":"crossref","first-page":"17755","DOI":"10.1016\/S0021-9258(19)77900-9","article-title":"Man, apes, and Old World monkeys differ from other mammals in the expression of \u03b1-galactosyl epitopes on nucleated cells","volume":"263","author":"Galili","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0250","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1016\/S0021-9258(17)42779-7","article-title":"Occurrence of \u03b1-D-galactosyl residues in the thyroglobulin from several species. Localization in the saccharide chains of the complex carbohydrate units","volume":"259","author":"Spiro","year":"1984","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0255","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1021\/bi00468a024","article-title":"Distribution of Gal\u03b11-3Gal\u03b21-4GlcNAc residues on secreted mammalian glycoproteins (thyroglobulin, fibrinogen, and immunoglobulin G) as measured by a sensitive solid-phase radioimmunoassay","volume":"29","author":"Thall","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2020.08.032_b0260","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1073\/pnas.88.16.7401","article-title":"Gene sequences suggest inactivation of \u03b1-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys","volume":"88","author":"Galili","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0265","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajpa.23745","article-title":"Evolution in primates by \u201cCatastrophic-selection\u201d interplay between enveloped virus epidemics, mutated genes of enzymes synthesizing carbohydrate antigens, and natural anti-carbohydrate antibodies","volume":"168","author":"Galili","year":"2019","journal-title":"Am J Phys Anthropol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1399-3089.2002.1o058.x","article-title":"Anti-Gal \u03b11-3Gal IgM and IgG antibody levels in sera of humans and Old World non-human primates","volume":"9","author":"Teranishi","year":"2002","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0275","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1099\/0022-1317-75-5-1177","article-title":"Differential host dependent expression of \u03b1-galactosyl epitopes on viral glycoproteins: A study of Eastern equine encephalitis virus as a model","volume":"75","author":"Repik","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0280","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1084\/jem.182.5.1345","article-title":"A novel mechanism of retrovirus inactivation in human serum mediated by anti-\u03b1-galactosyl natural antibody","volume":"182","author":"Rother","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0285","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/JVI.72.6.4650-4656.1998","article-title":"Evaluation of the Gal\u03b11-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses","volume":"72","author":"Welsh","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0290","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/379085a0","article-title":"Sensitization of cells and retroviruses to human serum by (\u03b11-3) galactosyltransferase","volume":"379","author":"Takeuchi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.08.032_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2003.09.008","article-title":"The neutralization of pseudorabies virus by anti-\u03b1-galactosyl natural antibody in normal serum","volume":"99","author":"Hayashi","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0300","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2004-11-4267","article-title":"HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation","volume":"105","author":"Neil","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2020.08.032_b0305","first-page":"1254","article-title":"Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation","volume":"37","author":"D\u00fcrrbach","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0310","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood.V99.7.2477","article-title":"Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement","volume":"99","author":"Preece","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2020.08.032_b0315","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-3089.2007.00377.x","article-title":"Natural protection from zoonosis by \u03b1-gal epitopes on virus particles in xenotransmission","volume":"14","author":"Kim","year":"2007","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0320","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0264-410X(95)00189-8","article-title":"Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody","volume":"14","author":"Galili","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0325","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0264-410X(96)00300-3","article-title":"Synthesis of \u03b1-gal epitopes on influenza virus vaccines, by recombinant \u03b11,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody","volume":"15","author":"Henion","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0330","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.4049\/jimmunol.178.7.4676","article-title":"Intratumoral injection of \u03b1-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines","volume":"178","author":"Galili","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0335","doi-asserted-by":"crossref","first-page":"21437","DOI":"10.1074\/jbc.270.37.21437","article-title":"Oocyte Gal\u03b1 1,3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse","volume":"270","author":"Thall","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0340","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI7358","article-title":"Differential immune responses to \u03b1-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation","volume":"105","author":"Tanemura","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.08.032_b0345","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/eji.1830211136","article-title":"Exact prediction of a natural T cell epitope","volume":"21","author":"R\u00f6tzschke","year":"1991","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0350","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.4049\/jimmunol.150.7.2724","article-title":"Endogenous generation and presentation of the ovalbumin peptide\/Kb complex to T cells","volume":"150","author":"Shastri","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0355","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/bi00270a028","article-title":"Carbohydrates of influenza virus hemagglutinin: structures of the whole neutral sugar chains","volume":"22","author":"Matsumoto","year":"1983","journal-title":"Biochemistry"},{"key":"10.1016\/j.vaccine.2020.08.032_b0360","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/j.1460-2075.1985.tb03991.x","article-title":"Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis","volume":"4","author":"Keil","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2020.08.032_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(79)90389-8","article-title":"Immunochemical studies of the combining sites of the two isolectins, A4 and B4, isolated from Bandeiraea simplicifolia","volume":"198","author":"Wood","year":"1979","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.vaccine.2020.08.032_b0370","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/infdis\/173.1.60","article-title":"Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors","volume":"173","author":"Montefiori","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.032_b0375","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1128\/JVI.79.12.7933-7937.2005","article-title":"Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0380","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri1417","article-title":"HIV and SIV CTL escape: implications for vaccine design","volume":"4","author":"Goulder","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0385","doi-asserted-by":"crossref","first-page":"15614","DOI":"10.1073\/pnas.1413550111","article-title":"Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development","volume":"111","author":"Lewis","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0390","doi-asserted-by":"crossref","first-page":"9145","DOI":"10.1128\/JVI.73.11.9145-9152.1999","article-title":"Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses","volume":"73","author":"Qiu","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0395","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virusres.2004.02.030","article-title":"A \u201cuniversal\u201d human in fluenza A vaccine","volume":"103","author":"Fiers","year":"2004","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0400","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4049\/jimmunol.1801054","article-title":"Development of a Universal Influenza Vaccine","volume":"202","author":"Estrada","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0405","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/eji.200526146","article-title":"The influence of natural antibody specificity on antigen immunogenicity","volume":"35","author":"Benatuil","year":"2005","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.vaccine.2020.08.032_b0410","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-3083.2006.01818.x","article-title":"Antibody-mediated regulation of the Immune response","volume":"64","author":"Hjelm","year":"2006","journal-title":"Scand J Immunol."},{"key":"10.1016\/j.vaccine.2020.08.032_b0415","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00007890-199607270-00018","article-title":"Inhibition of anti-Gal IgG binding to porcine endothelial cells by synthetic oligosaccharides","volume":"62","author":"Galili","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0420","first-page":"3417","article-title":"Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for \u03b11,3galactosyltransferase","volume":"59","author":"LaTemple","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0425","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1158\/0008-5472.CAN-05-0627","article-title":"Effective treatment of preexisting melanoma with whole cell vaccines expressing \u03b1(1,3)-galactosyl epitopes","volume":"65","author":"Rossi","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0430","first-page":"625","article-title":"Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells","volume":"90","author":"Manches","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2020.08.032_b0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4049\/jimmunol.157.2.541","article-title":"Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells","volume":"157","author":"Fanger","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0440","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/glycob\/4.2.193","article-title":"Defining the minimal size of catalytically active primate \u03b11,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme","volume":"4","author":"Henion","year":"1994","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2020.08.032_b0445","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/glycob\/11.7.577","article-title":"Synthesis of \u03b1-gal epitopes (Gal\u03b11-3Gal\u03b21-4GlcNAc-R) on human tumor cells by recombinant \u03b11,3galactosyltransferase produced in Pichia cells lacking \u03b1-gal epitopes and pastoris","volume":"11","author":"Chen","year":"2001","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2020.08.032_b0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184901","article-title":"A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express \u03b1-gal epitopes","volume":"12","author":"Furukawa","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.08.032_b0455","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0090-8258(03)00148-3","article-title":"Expression of \u03b1-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccine","volume":"90","author":"Galili","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0460","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.3748\/wjg.v17.i48.5260","article-title":"Hepatocellular carcinoma-specific immunotherapy with synthesized \u03b11,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells","volume":"17","author":"Qiu","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0465","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10147-012-0434-4","article-title":"Pancreatic carcinoma-specific immunotherapy using synthesized \u03b1-galactosyl epitope-activated immune responders: findings from a pilot study","volume":"18","author":"Qiu","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcyt.2015.09.012","article-title":"Combination of cytokine-induced killer and dendritic cells pulsed with antigenic \u03b1-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy","volume":"18","author":"Qiu","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.vaccine.2020.08.032_b0475","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1432-1033.1990.tb19095.x","article-title":"\u03b11-3-galactosyltransferase: the use of recombinant enzyme for the synthesis of \u03b1-galactosylated glycoconjugates","volume":"191","author":"Joziasse","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0480","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1016\/S0021-9258(19)39314-7","article-title":"Transfer and expression of a murine UDP-Gal\u03b2-D-Gal-\u03b11,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. Competition reactions between the \u03b11,3-galactosyltransferase and the endogenous \u03b12,3-sialyltransferase","volume":"265","author":"Smith","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0485","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1086\/605505","article-title":"Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture","volume":"200","author":"Szymczakiewicz-Multanowska","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.08.032_b0490","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2009.07.083","article-title":"A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine","volume":"27","author":"Ambrozaitis","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.08.032_b0495","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/glycob\/12.2.135","article-title":"Expression of \u03b1-gal epitopes on HeLa cells transduced with adenovirus containing \u03b11,3galactosyltransferase cDNA","volume":"12","author":"Deriy","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2020.08.032_b0500","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0931263100","article-title":"Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris","volume":"100","author":"Choi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.08.032_b0505","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrmicro1087","article-title":"The humanization of N-glycosylation pathways in yeast","volume":"3","author":"Wildt","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0510","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00253-010-2718-9","article-title":"Extracellular accumulation of recombinant protein by Escherichia coli in a defined medium","volume":"88","author":"Fu","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0515","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/AEM.01901-10","article-title":"Production of secretory and extracellular N-linked glycoproteins in Escherichia coli","volume":"77","author":"Fisher","year":"2011","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0520","doi-asserted-by":"crossref","first-page":"31594","DOI":"10.1074\/jbc.M004005200","article-title":"Changing the donor cofactor of bovine \u03b11,3-galactosyltransferase by fusion with UDP-galactose 4-epimerase. More efficient biocatalysis for synthesis of \u03b1-Gal epitopes","volume":"275","author":"Chen","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.08.032_b0525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.carres.2012.05.015","article-title":"Synthesis of \u03b1-galactosyl epitopes by metabolically engineered Escherichia coli","volume":"361","author":"Gebus","year":"2012","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0530","doi-asserted-by":"crossref","unstructured":"Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002;298:1790\u20133.","DOI":"10.1126\/science.298.5599.1790"},{"key":"10.1016\/j.vaccine.2020.08.032_b0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00007890-199601150-00004","article-title":"The \u03b1-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation","volume":"61","author":"Tearle","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0540","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.1068228","article-title":"Production of \u03b1-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning","volume":"295","author":"Lai","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.032_b0545","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1126\/science.1078942","article-title":"Production of \u03b11,3-galactosyltransferase-deficient pigs","volume":"299","author":"Phelps","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2020.08.032_b0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1399-3089.1998.tb00027.x","article-title":"Adult and neonatal anti-Gal response in knock-out mice for \u03b11,3galactosyltransferase","volume":"5","author":"LaTemple","year":"1998","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0555","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.TP.0000130487.68051.EB","article-title":"\u03b11,3-Galactosyltransferase gene-knockout miniature swine produce natural cytotoxic anti-Gal antibodies","volume":"78","author":"Dor","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0560","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1399-3089.2012.00710.x","article-title":"Anti-gal antibodies in \u03b11,3-galactosyltransferase gene-knockout pigs","volume":"19","author":"Fang","year":"2012","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0565","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/xen.12051","article-title":"\u03b11,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates","volume":"20","author":"Galili","year":"2013","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.vaccine.2020.08.032_b0570","first-page":"3861","article-title":"Cancer immunotherapy by intratumoral injection of \u03b1-gal glycolipids","volume":"32","author":"Whalen","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2020.08.032_b0575","doi-asserted-by":"crossref","unstructured":"Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, et al. Phase I study to evaluate toxicity and feasibility of intratumoral injection of \u03b1-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother 65, 897\u2013907.","DOI":"10.1007\/s00262-016-1846-1"},{"key":"10.1016\/j.vaccine.2020.08.032_b0580","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.08.032_b0585","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2008.10.052","article-title":"Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-\u03b1-1,3-galactose","volume":"123","author":"Commins","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0590","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jaci.2011.07.020","article-title":"Delayed mammalian meat-induced anaphylaxis due to galactose-\u03b1-1,3-galactose in 5 European patients","volume":"128","author":"Nunez","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0595","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/ACI.0b013e3283624560","article-title":"Tick bites and red meat allergy","volume":"13","author":"Commins","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.08.032_b0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5415\/apallergy.2015.5.1.3","article-title":"Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance","volume":"5","author":"van Nunen","year":"2015","journal-title":"Asia Pac Allergy"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20310732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:18Z","timestamp":1759402098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20310732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":120,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20310732"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present \u03b1-gal epitopes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}